Finally, clinical data revealed that low expression of RADX and SMARCAL1 correlates with poorer prognosis of BRCA1/2-mutated cancer patients, confirming the important role of fork stabilization in modulating chemosensitivities [59,60,61]. The gene discussed is BRCA1; the disease is cancer.